28 maart 2017 Lees ook dit artikel:

https://kanker-actueel.nl/NL/immuuntherapie-met-het-gemoduleerde-virus-ankara5t4-trovax-plus-lage-dosis-cyclophosphamide-zorgt-voor-verdubbeling-van-mediane-overall-overleving-112-vs-20-maanden-bij-vergevorderde-darmkanker.html

En zie ook gerelateerde artikelen

4 mei 2012: HSPPC-96, een vorm van dendritische celtherapie heeft ook bij hersentumoren uitstekende resultaten laten zien. klik hier voor artikelen daarover.

Mei 2011:

Het vaccin Oncophage(R) (HSPPC-96) geeft in Fase II studies opmerkelijk goede resultaten. Bij 29 patiënten met uitgezaaide darmkanker zorgde het vaccin bij de patiënten waar de immuunfunctie op gang kwam - de helft van de deelnemende patiënten reageerde hier goed op -  voor 100 % resultaat gedurende twee jaar. Dit resultaat bevestigt de eerdere resultaten uit een grote fase II studie bij darmkankerpatiënten die stop is gezet in Nederland omdat er geen geld voor beschikbaar is om het onderzoek verder uit te voeren. In die studies was het resultaat 61% in positieve zin. Zie kankersoorten-darmkankers. Lees ook informatie over dendritische celtherapie wat deze vorm van immuuntherapie in feite is.

 

Bron: DOW-New York

Two-Year Survival Rate of 100 Percent in
Subjects Who Responded Immunologically to Oncophage(R)

Antigenics Inc. (NASDAQ: AGEN), the world leader in heat shock protein
technology, announced today that results from a Phase II clinical trial of the
company's personalized cancer vaccine Oncophage(R) (HSPPC-96) in patients with
metastatic colorectal cancer were published as a featured article in the August
15, 2003 issue of Clinical Cancer Research. In the study, more than half of the
29 patients who received Oncophage demonstrated significant immunological
response - which not only appeared to be correlated with clinical response but
also found to be an independent factor for prognosis.
"These findings provide encouraging support that immunological response to
Oncophage vaccination may be associated with clinical benefit in this patient
population," said Jonathan J. Lewis, MD, PhD, chief medical officer of
Antigenics. "In addition, the observed immunological mechanism of action has
been found to be consistent across all cancer types evaluated to date, which
supports the notion that Oncophage may be useful in the treatment of a broad
range of cancers."
Derived from each individual's tumor, Oncophage contains the 'antigenic
fingerprint' of the patient's particular cancer, and is designed to reprogram
the body's immune system to target and destroy only cancer cells bearing this
fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit
the debilitating side effects associated with traditional cancer treatments such
as chemotherapy and radiation therapy.

Promising Clinical and Immunological Findings

The study evaluated 29 patients with stage IV colorectal cancer that had
spread to the liver, who had undergone complete resection (surgical removal) of
their metastasized disease. Surgery, which provided the tumor tissue used to
produce the personalized Oncophage vaccines, was followed by two cycles of
Oncophage treatment for all patients.
Researchers determined that immune response to Oncophage vaccination is an
independent factor for prognosis and appears to be associated with clinical
benefit in this patient population. In the trial, patients who responded
immunologically to the vaccine (52 percent of study subjects) had a
statistically significant survival advantage compared with patients who did not
respond immunologically. Responders demonstrated a two-year overall survival
rate of 100 percent, compared with 50 percent for nonresponders, and a
disease-free survival rate of 51 percent, compared with 8 percent among
nonresponders.
Patients who demonstrated immune response to Oncophage treatment also
experienced a significantly lower rate of recurrence (41 percent) compared with
nonresponding patients (92 percent).
Currently in Phase III clinical trials for metastatic melanoma and kidney
cancer, other clinical research evaluating Oncophage includes studies in several
other cancers such as lymphoma, and pancreatic and gastric cancers. Oncophage
has been granted fast track and orphan drug designations from the US Food and
Drug Administration in both metastatic melanoma and kidney cancer.

About Colorectal Cancer

Together, cancers of the colon and rectum are among the most common cancers in
the United States. This year, it is estimated that there will be about 107,300
new cases of colon cancer and 41,000 new cases of rectal cancer, together
causing almost 57,000 deaths. They occur in both men and women and are most
often found among people who are over the age of 50. The three main types of
treatment for colorectal cancer are surgery, radiation therapy and chemotherapy.

About Antigenics

Antigenics is working to develop personalized immunotherapeutics and
revolutionary treatments for cancers, infectious diseases and autoimmune
disorders. The company's lead product candidate is Oncophage, a late-stage,
personalized cancer vaccine being evaluated in several indications, including
kidney cancer and metastatic melanoma. Antigenics' portfolio also includes
AG-858, a personalized cancer vaccine in Phase II development; Aroplatin(TM) and
ATRA-IV, two Phase II liposomal chemotherapeutics; and AG-702/AG-70X, a Phase I
genital herpes immunotherapeutic. For more information about Antigenics, please
visit www.antigenics.com.
This press release contains forward-looking statements, including the
statements regarding the apparent correlation between immune response to
Oncophage vaccination and clinical response and benefit, and the potential
utility of Oncophage in the treatment of a broad range of cancers. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially from those projected in these forward-looking
statements. These risks and uncertainties include, among others, that our
clinical trials may not demonstrate that our products are both safe and more
effective than current standards of care; that we may be unable to obtain the
regulatory approvals necessary to conduct additional clinical trials or to
market our products; that budget constraints will limit or slow down our
development programs; that we may fail to adequately protect our intellectual
property or are determined to infringe on the intellectual property of others;
and the factors described in the company's periodic filings with the Securities
and Exchange Commission. Please see the "Factors That May Impact Future Results"
section of the Management's Discussion and Analysis of Financial Condition and
Results of Operations in the Antigenics Quarterly Report on Form 10-Q for the
quarter ended June 30, 2003, for a full discussion of these and other risk
factors. Antigenics cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. These statements
speak only as of the date of this document, and Antigenics undertakes no
obligation to update or revise the statements. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.


Plaats een reactie ...

Reageer op "Immuuntherapie: Oncophage(R) (HSPPC-96), gemaakt van eigen tumorcellen zorgt voor opmerkelijke resultaten bij o.a. darmkanker."


Gerelateerde artikelen
 

Gerelateerde artikelen

Dendritische cellen en Newcastle >> Autologe genetisch gemodificeerde >> Man met uitgezaaide darmkanker >> Nivolumab (Opvido) + ipilimumab >> Immuuntherapie met een gemoduleerd >> Man met uitgezaaide inoperabele >> Immuuntherapie met autovaccinatie >> Immuuntherapie met dendritische >> Xilonix - MAPp1 zorgt voor >> Dendritische cellen en Newcastle >>